https://www.complementtx.com/blog 1.0 monthly 2026-07-14 https://www.complementtx.com/patient-information 1.0 monthly 2026-07-14 https://www.complementtx.com/investor-presentation 1.0 monthly 2026-07-14 https://www.complementtx.com/science 1.0 monthly 2026-07-14 https://www.complementtx.com 1.0 monthly 2026-07-15 https://www.complementtx.com/platform 1.0 monthly 2026-07-14 https://www.complementtx.com/copy-of-home 1.0 monthly 2026-07-14 https://www.complementtx.com/about-us 1.0 monthly 2026-07-14 https://www.complementtx.com/investors 1.0 monthly 2026-07-15 https://www.complementtx.com/our-research 1.0 monthly 2026-07-14 https://www.complementtx.com/clinical-trials 1.0 monthly 2026-07-15 https://www.complementtx.com/technology 1.0 monthly 2026-07-14 https://www.complementtx.com/careers 1.0 monthly 2026-07-14 https://www.complementtx.com/board-of-directors 1.0 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-announces-completion-of-cohort-1-dosing-and-favourable-independent-data-monitoring-committee-recommendation-in-the-phase-i-ii-opti-gain-study-for-geographic-atrophy-secondary-t 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-announces-first-patient-dosed-with-ctx001-in-the-phase-i-ii-opti-gain-study-for-geographic-atrophy-secondary-to-amd 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-receives-uk-cta-approval-to-advance-ctx001-into-opti-gain-phase-i-ii-clinical-trial-in-geographic-atrophy-secondary-to-amd 0.8 monthly 2026-07-14 https://www.complementtx.com/touchlight-cell-and-gene-therapy-catapult-and-complement-therapeutics-to-develop-innovative-manufacturing-process-for-gene-therapies 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-appoints-dr-muhammad-ali-memon-frcophth-as-chief-medical-officer 0.8 monthly 2026-07-14 https://www.complementtx.com/complement therapeutics receives fda ind clearance to advance ctx001 into opti-gain, a phase i/ii clinical trial in geographic atrophy secondary to amd 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-receives-fda-ind-clearance-to-advance-ctx001-into-opti-gain-a-phase-i-ii-clinical-trial-in-geographic-atrophy-secondary-to-amd 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-announces-fda-fast-track-designation-for-ctx001-for-the-treatment-of-geographic-atrophy-secondary-to-amd 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-announces-the-establishment-of-medical-advisory-boarda6195022 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-announces-the-establishment-of-medical-advisory-board 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-appoints-dr-matthias-hebben-as-chief-technology-officer 0.8 monthly 2026-07-14 https://www.complementtx.com/complement-therapeutics-enrols-first-us-participant-in-the-non-interventional-i-gain-study-of-people-diagnosed-with-geographic-atrophy 0.8 monthly 2026-07-14